ATLnsider: Question...
As I ponder the next sequence of events with NWBO (i.e. TLD, Sawston Update, SNO, etc.) I keep coming back to the Merck employee who joined NWBO for a while then when back to Merck and the Keytruda co-treatment.
Although I view the following a low probability, but what are your thoughts on the possibility that the Merck employee was there to help design a co-treatment regime that would be used in the PIII?
If the subset of the patients treated this way show significance, then I can understand why "KIRK" keeps posting that a potential buyout could be at hand.
Although to maximize any buyout offer, it appears a company needs regulatory approval for the treatment as well as for the treatment's manufacturing process.
Thoughts? Thank you very much in advance....
News 
Market Data 
Discover 
AI
